Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630679 | 0.78 | PSEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL1631329 | 0.77 | CES2 (0.39) | CES2CES1GRIN1GRIN2B | |
| SCHEMBL1630858 | 0.77 | CES2 (0.35) | CYP11B1CYP11B2CES2CES1 | |
| SCHEMBL1633218 | 0.76 | PSEN1 (0.46) | — | |
| SCHEMBL27648391 | 0.76 | CES2 (0.40) | CYP11B1CYP11B2CES2CES1 | |
| SCHEMBL1632427 | 0.75 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL1632053 | 0.68 | MAPT (0.47) | CES2CES1PRKDCKCNH2 | |
| SCHEMBL8549951 | 0.68 | KCNH2 (0.48) | MEN1KMT2ACYP11B1CYP11B2KCNH2 | |
| SCHEMBL166382 | 0.66 | MEN1 (0.38) | MEN1KMT2ACYP11B1CYP11B2KCNH2 | |
| SCHEMBL1964902 | 0.64 | MEN1 (0.50) | MEN1KMT2ACYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7932271-B2 | Heterocyclic methyl sulfone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-04-26 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-7399775-B2 | β-amyloid protein production/secretion inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-20 | — | — | US | disclosed |
| US-20060241302-A1 | Morpholine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
| EP-1640366-A1 | HETEROCYCLIC METHYL SULFONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-03-29 | — | — | EP | disclosed |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | DAIICHI PHARMACEUTICAL CO. LTD. (JP) | 2005-10-20 | — | — | US | disclosed |
| EP-1466898-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241302-A1 | Morpholine derivatives | APP, BACE1, SMS | MEN1 231/4885KMT2A 3864/4885CYP11B1 29/4885 |
| US-20050234109-A1 | to treat Alzheimer's disease,Down syndrome and the other diseases associated with amyloid deposition; thiomethane, sulfinylmethane or sulfonylmethane compounds; 5-Chloro-4-[(4-chlorophenylsulfonyl)-(2,5-difluorophenyl)methyl]-2-(4'-hydroxypiperidin-1'-yl)pyridine | APP, PSEN1, PSEN2 | MEN1 2460/4885KMT2A 1527/4885CYP11B1 2215/4885 |
| US-20070293495-A1 | BETA-AMYLOID PROTEIN PRODUCTION/SECRETION INHIBITORS | APP, IAPP, BACE1 | MEN1 787/4885KMT2A 4830/4885CYP11B1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.